Scientists use alpaca antibodies to make new pandemic flu drug
Trial could ‘usher in a new era’ of affordable antibody therapies to protect against dangerous infectious diseases like Mers, ...
Interesting Engineering on MSN1 天
Lepodisiran drug shows unprecedented 94% drop in heart disease risk factor: Study
Eli Lilly and Company announced encouraging results from a Phase 2 trial of lepodisiran, an investigational therapy aimed at ...
pharmaphorum2 天
ACC25: Positive results with Lilly's Lp(a)-lowering drug
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
The Pharma Letter1 天
Lilly reports lasting drop in heart risk factor with new drug
US pharma major Eli Lilly (NYSE: LLY) has unveiled new Phase II data showing that its RNA-based therapy lepodisiran produced ...
Precision Medicine Online1 天
Eli Lilly Drug Cuts Lp(a) in Trial, Raising Its Prospects for Treating Cardiovascular Disease
Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...
Applied Clinical Trials Online1 天
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a ...
Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...
PharmiWeb2 天
Lilly's lepodisiran reduced levels of genetically…
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...
Lilly's Lepodisiran Achieves 94% Heart Disease Risk Reduction in Groundbreaking Phase 2 Trial
Lilly's lepodisiran shows a 94% reduction in heart disease risk by lowering lipoprotein(a) levels, offering a breakthrough in cardiovascular innovation.